S&P 500   2,610.76 (+2.73%)
DOW   22,145.49 (+2.35%)
QQQ   191.28 (+3.23%)
AAPL   252.84 (+2.06%)
FB   165.87 (+5.79%)
MSFT   159.37 (+6.67%)
GOOGL   1,139.68 (+2.68%)
AMZN   1,951.84 (+2.72%)
CGC   14.32 (-1.85%)
NVDA   262.83 (+4.00%)
BABA   189.96 (+0.73%)
MU   44.18 (+1.61%)
GE   7.83 (+2.76%)
TSLA   503.98 (-2.02%)
AMD   47.56 (+2.10%)
T   30.01 (+0.54%)
ACB   0.87 (-15.53%)
F   4.98 (-4.05%)
NFLX   373.20 (+4.50%)
BAC   22.03 (+1.99%)
GILD   75.87 (+4.15%)
PRI   91.09 (+2.28%)
DIS   98.17 (+1.84%)
S&P 500   2,610.76 (+2.73%)
DOW   22,145.49 (+2.35%)
QQQ   191.28 (+3.23%)
AAPL   252.84 (+2.06%)
FB   165.87 (+5.79%)
MSFT   159.37 (+6.67%)
GOOGL   1,139.68 (+2.68%)
AMZN   1,951.84 (+2.72%)
CGC   14.32 (-1.85%)
NVDA   262.83 (+4.00%)
BABA   189.96 (+0.73%)
MU   44.18 (+1.61%)
GE   7.83 (+2.76%)
TSLA   503.98 (-2.02%)
AMD   47.56 (+2.10%)
T   30.01 (+0.54%)
ACB   0.87 (-15.53%)
F   4.98 (-4.05%)
NFLX   373.20 (+4.50%)
BAC   22.03 (+1.99%)
GILD   75.87 (+4.15%)
PRI   91.09 (+2.28%)
DIS   98.17 (+1.84%)
S&P 500   2,610.76 (+2.73%)
DOW   22,145.49 (+2.35%)
QQQ   191.28 (+3.23%)
AAPL   252.84 (+2.06%)
FB   165.87 (+5.79%)
MSFT   159.37 (+6.67%)
GOOGL   1,139.68 (+2.68%)
AMZN   1,951.84 (+2.72%)
CGC   14.32 (-1.85%)
NVDA   262.83 (+4.00%)
BABA   189.96 (+0.73%)
MU   44.18 (+1.61%)
GE   7.83 (+2.76%)
TSLA   503.98 (-2.02%)
AMD   47.56 (+2.10%)
T   30.01 (+0.54%)
ACB   0.87 (-15.53%)
F   4.98 (-4.05%)
NFLX   373.20 (+4.50%)
BAC   22.03 (+1.99%)
GILD   75.87 (+4.15%)
PRI   91.09 (+2.28%)
DIS   98.17 (+1.84%)
S&P 500   2,610.76 (+2.73%)
DOW   22,145.49 (+2.35%)
QQQ   191.28 (+3.23%)
AAPL   252.84 (+2.06%)
FB   165.87 (+5.79%)
MSFT   159.37 (+6.67%)
GOOGL   1,139.68 (+2.68%)
AMZN   1,951.84 (+2.72%)
CGC   14.32 (-1.85%)
NVDA   262.83 (+4.00%)
BABA   189.96 (+0.73%)
MU   44.18 (+1.61%)
GE   7.83 (+2.76%)
TSLA   503.98 (-2.02%)
AMD   47.56 (+2.10%)
T   30.01 (+0.54%)
ACB   0.87 (-15.53%)
F   4.98 (-4.05%)
NFLX   373.20 (+4.50%)
BAC   22.03 (+1.99%)
GILD   75.87 (+4.15%)
PRI   91.09 (+2.28%)
DIS   98.17 (+1.84%)
Log in

NASDAQ:TWST - Twist Bioscience Stock Price, Forecast & News

$31.82
+1.82 (+6.07 %)
(As of 03/30/2020 03:30 PM ET)
Today's Range
$30.04
Now: $31.82
$34.02
50-Day Range
$19.71
MA: $29.56
$35.15
52-Week Range
$18.52
Now: $31.82
$35.95
Volume559,303 shs
Average Volume641,351 shs
Market Capitalization$1.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.04
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. Twist Bioscience Corporation has a collaboration agreement with Pandion Therapeutics, Inc. to apply its antibody optimization platform for a targeting arm of a bispecific antibody. The company was founded in 2013 and is headquartered in San Francisco, California.
Read More

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TWST
CUSIPN/A
CIKN/A
Phone800-719-0671

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$54.38 million
Book Value$4.63 per share

Profitability

Net Income$-107,670,000.00
Net Margins-234.22%

Miscellaneous

Employees289
Market Cap$1.13 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableNot Optionable

Receive TWST News and Ratings via Email

Sign-up to receive the latest news and ratings for TWST and its competitors with MarketBeat's FREE daily newsletter.


Twist Bioscience (NASDAQ:TWST) Frequently Asked Questions

How has Twist Bioscience's stock been impacted by COVID-19 (Coronavirus)?

Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, TWST stock has increased by 12.8% and is now trading at $31.82. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Twist Bioscience?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Twist Bioscience.

When is Twist Bioscience's next earnings date?

Twist Bioscience is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Twist Bioscience.

How were Twist Bioscience's earnings last quarter?

Twist Bioscience Corp (NASDAQ:TWST) posted its earnings results on Thursday, February, 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.83) by $0.17. The business had revenue of $17.20 million for the quarter, compared to the consensus estimate of $16.06 million. Twist Bioscience had a negative return on equity of 86.44% and a negative net margin of 234.22%. Twist Bioscience's quarterly revenue was up 49.6% compared to the same quarter last year. View Twist Bioscience's earnings history.

What guidance has Twist Bioscience issued on next quarter's earnings?

Twist Bioscience issued an update on its FY 2020 After-Hours earnings guidance on Thursday, February, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $80-84 million, compared to the consensus revenue estimate of $82.52 million.

What price target have analysts set for TWST?

2 Wall Street analysts have issued twelve-month price objectives for Twist Bioscience's shares. Their forecasts range from $42.00 to $42.00. On average, they anticipate Twist Bioscience's stock price to reach $42.00 in the next year. This suggests a possible upside of 32.0% from the stock's current price. View analysts' price targets for Twist Bioscience.

Has Twist Bioscience been receiving favorable news coverage?

Headlines about TWST stock have trended very positive this week, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Twist Bioscience earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutTwist Bioscience.

Are investors shorting Twist Bioscience?

Twist Bioscience saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 2,973,800 shares, an increase of 6.2% from the February 27th total of 2,800,000 shares. Based on an average daily volume of 587,700 shares, the short-interest ratio is currently 5.1 days. Approximately 21.4% of the company's shares are sold short. View Twist Bioscience's Current Options Chain.

Who are some of Twist Bioscience's key competitors?

What other stocks do shareholders of Twist Bioscience own?

Who are Twist Bioscience's key executives?

Twist Bioscience's management team includes the following people:
  • Dr. Emily Marine Leproust, Co-Founder, Pres, CEO & Director (Age 45)
  • Mr. James M. Thorburn, Chief Financial Officer (Age 64)
  • Mr. Mark Daniels Esq., Sr. VP, Chief Legal Officer, Gen. Counsel, Chief Ethics & Compliance Officer and Sec. (Age 56)
  • Mr. William Charles Banyai, COO & Director (Age 64)
  • Mr. Bill Peck, Chief Technology Officer (Age 59)

When did Twist Bioscience IPO?

(TWST) raised $75 million in an IPO on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen served as the underwriters for the IPO and Allen & Company and Baird were co-managers.

What is Twist Bioscience's stock symbol?

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Who are Twist Bioscience's major shareholders?

Twist Bioscience's stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (2.67%), Capital World Investors (1.99%), Lord Abbett & CO. LLC (1.57%), FMR LLC (1.52%), Alyeska Investment Group L.P. (1.37%) and Massachusetts Financial Services Co. MA (1.36%). Company insiders that own Twist Bioscience stock include Bill Peck, James M Thorburn, Keith Crandell, Mark Daniels, Patrick John Finn, Patrick Weiss and William Banyai. View institutional ownership trends for Twist Bioscience.

Which institutional investors are selling Twist Bioscience stock?

TWST stock was sold by a variety of institutional investors in the last quarter, including Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Barclays PLC, UBS Group AG, Windsor Creek Advisors LLC, FMR LLC, Nuveen Asset Management LLC, and Rafferty Asset Management LLC. Company insiders that have sold Twist Bioscience company stock in the last year include Bill Peck, James M Thorburn, Mark Daniels, Patrick John Finn, Patrick Weiss, and William Banyai. View insider buying and selling activity for Twist Bioscience.

Which institutional investors are buying Twist Bioscience stock?

TWST stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, Alyeska Investment Group L.P., ARK Investment Management LLC, Massachusetts Financial Services Co. MA, Lord Abbett & CO. LLC, Perceptive Advisors LLC, Perceptive Advisors LLC, and Algert Global LLC. View insider buying and selling activity for Twist Bioscience.

How do I buy shares of Twist Bioscience?

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Twist Bioscience's stock price today?

One share of TWST stock can currently be purchased for approximately $31.82.

How big of a company is Twist Bioscience?

Twist Bioscience has a market capitalization of $1.13 billion and generates $54.38 million in revenue each year. The company earns $-107,670,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis. Twist Bioscience employs 289 workers across the globe. View additional information about Twist Bioscience.

What is Twist Bioscience's official website?

The official website for Twist Bioscience is http://www.twistbioscience.com/.

How can I contact Twist Bioscience?

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 800-719-0671 or via email at [email protected]


MarketBeat Community Rating for Twist Bioscience (NASDAQ TWST)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  55 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  115
MarketBeat's community ratings are surveys of what our community members think about Twist Bioscience and other stocks. Vote "Outperform" if you believe TWST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TWST will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel